Kiniksa Pharmaceuticals International, plc (KNSA)

As of 31 August 2026, short interest in KNSA is 3,788,699 shares, down 528,160 shares over the last month. Over the last 48 readings it ranged from 1,929,100 shares (31 January 2025) to 4,636,433 shares (13 September 2024). At the reported average volume of 436K shares a day that is 8.7 days to cover, elevated.

<iframe src="https://xoomar.com/embed/stocks/knsa" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of KNSA volume is 38.1%, down 11.4 points over the last five sessions. Over the last 52 readings it ranged from 31.3% (31 July 2026) to 80.5% (13 August 2026). The latest reading is 13.9 points below the 30-session average of 52.0%, on 147K shares reported.

As of 11 August 2026, the fails-to-deliver balance in KNSA is 543 shares, up 537 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (29 December 2025) to 33,792 shares (20 May 2025). The latest reading sits at the bottom of that range.

Insiders at KNSA reported 1 open-market sell worth $299K in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Quart Barry D on 2026-08-19.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

3 Form 144 notices on file for KNSA worth $6.0M at the prices reported; 3 in the last 90 days worth $6.0M. Latest: Megna Michael R filed on 2026-09-03 to sell 4,600 shares ($369K) from 2026-09-03.

11 holders above 5% have filed on KNSA, 5 on Schedule 13D (active intent). The largest reported stake is FMR LLC at 14.8% of the class (6,787,700 shares), filed 2026-05-06 for an event on 2026-03-31.

8 of the 30 tracked managers held KNSA at their latest 13F, $178.2M in total at quarter-end prices. Point72 Asset Management is the largest at $42.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 5 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q1 2026 (quarter ended 2026-03-31) Kiniksa Pharmaceuticals International, plc reported revenue of $214.3M, up 55.5% from the same quarter a year earlier, and net income of $22.6M (0.27 diluted EPS). In FY 2025 it generated $138.0M of operating cash flow.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-03-31.